Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination therapy for combined dyslipidemia.

Antonios M Xydakis1, Christie M Ballantyne

  • 1Division of Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA.

The American Journal of Cardiology
|December 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adrenal Failure and Orchitis Secondary to Tuberculosis Mimicking Metastatic Malignancy.

The American journal of medicine·2020
Same author

An <i>NPPB</i> Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality.

Journal of the American Heart Association·2017
Same author

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.

Clinical cardiology·2017
Same author

From Plaque Burden to Plaque Composition: Toward Personalized Risk Assessment.

JACC. Cardiovascular imaging·2017
Same author

Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.

JAMA cardiology·2017
Same author

Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials.

Circulation·2017

Patients with combined dyslipidemia need combination drug therapy for coronary artery disease risk. Optimal treatment requires further clinical trials to balance benefits and risks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Combined dyslipidemia presents a high risk for coronary artery disease.
  • The National Cholesterol Education Program's Adult Treatment Panel III (ATP III) provides lipid level guidelines.
  • Metabolic syndrome is common in combined dyslipidemia, increasing cardiovascular risk.

Purpose of the Study:

  • To review current treatment strategies for combined dyslipidemia.
  • To evaluate the role of combination drug therapy in managing lipid levels.
  • To identify emerging agents and future research needs.

Main Methods:

  • Literature review of clinical trials and treatment guidelines.
  • Analysis of statin monotherapy versus combination therapy benefits.

Related Experiment Videos

  • Evaluation of risks associated with combination therapies (e.g., myopathy).

    • Main Results:

    • Combination therapy may offer greater reductions in LDL cholesterol and triglycerides and increases in HDL cholesterol.
    • Combining statins with niacin or fibrates may increase myopathy risk.
    • New agents like ezetimibe and fixed-dose niacin-lovastatin show promise.

    Conclusions:

    • Combination therapy can be beneficial but requires careful risk-benefit assessment.
    • Further clinical trials are necessary to establish optimal treatment regimens.
    • Balancing efficacy, safety, cost, and compliance is crucial for managing combined dyslipidemia.